आईएसएसएन: 0974-276X
Kaushik S. Hatti, V. Chandregowda, G.Venkateswara Rao, Anil Kush and G.Chandrasekara Reddy
Epidermal growth factor receptor (EGFR) family has gained importance as a target for cancer therapy. However, somatic mutations in the tyrosine kinase domain of EGFR alter its sensitivity to anti-EGFR tyrosine kinase (TK) drugs like gefitinib (IressaTM). Docking studies of a few newly synthesized 6, 7-dialkoxy-4-anilinoquinazoline derivatives which showed EGFR-TK inhibitory activity were conducted. It has been found that the docking energies of these novel quniazolines are comparable with the IC50 values against A431 and MCF-7 tumor cell lines. Though the compounds with benzoxazole (1 & 2) and imidazole side chain (4) exhibited low binding energy to wild-type, but compound 3 had the lowest binding energy to its mutants as well (T790M, L858R and double-mutant). Compounds 1, 2, 4 and gefitinib showed affinity only for selective EGFR variants.